Miraculins Inc. on Life Science Investing News

Miraculins Inc.’s (TSXV:MOM) Scout DS® diabetes screening device non-invasively detects and measures biomarkers in the skin associated with pre-diabetes and type 2 diabetes. Miraculins has raised $18 million CDN to date and is considering filing a shelf prospectus at the end of the first quarter of 2015 to help with additional capital as it moves from a pre-revenue state to a manufacturing, sales and distribution organization.

Learn more about this company on Life Science Investing News.